Monomer Bio
Financials
Estimates*
USD | 2022 | 2023 |
---|---|---|
Revenues | <1m | <1m |
% growth | - | 167 % |
Date | Investors | Amount | Round |
---|---|---|---|
* | $5.6m | Seed | |
Total Funding | $5.6m |
Related Content
Recent News about Monomer Bio
EditMonomer Bio is a biotechnology company specializing in laboratory automation, particularly focusing on cell culture processes. The company operates in the life sciences market, catering to both preclinical and clinical research laboratories. Monomer Bio's core product is an automation software platform that integrates with existing lab hardware to streamline and optimize cell culture workflows. This solution allows researchers to schedule and manage complex protocols, such as directed differentiation and organoid maintenance, with ease and precision. By automating these processes, Monomer Bio helps labs achieve better data quality and faster results, reducing the need for manual intervention and weekend shifts.
Monomer Bio's business model involves selling its automation software and providing installation and validation services. The company also offers ongoing support and training to ensure that clients can effectively use the system. Revenue is generated through software licensing, hardware sales, and service fees.
The primary clients of Monomer Bio include research institutions, pharmaceutical companies, and biotech firms that require reliable and efficient cell culture solutions. The company leverages its team's expertise in modern lab hardware, software, and automation to deliver customized solutions that meet the specific needs of each client.
Keywords: laboratory automation, cell culture, biotechnology, research, software platform, hardware integration, preclinical, clinical, workflow optimization, data quality.